Data Reveals JAK Inhibitor Traction for RA

Article

Pharmaceutical Executive

Therapy Watch released data-which uses real-time patient record form data to monitor healthcare market dynamics-proposing that JAK inhibitors have made a strong impression on the Rheumatoid Arthritis (RA) market across France, Germany, Italy, Spain, and the UK (the EU5).

According to the study, JAK inhibitors have expanded their market share across the EU5 from 3.1% in Q3 2017 to 15.6% in Q2 2018. 

Recent Videos
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Most Effective Strategies to Close the Innovation Gap in Women’s Health
Root Causes of Innovation Gap in Women’s Health
Fred Aslan
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Fred Aslan
Related Content